ModeX Therapeutics, a subsidiary of OPKO Health, Launches Clinical Trial for MDX2004 Targeting Advanced Cancers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 28 2025
0mins
Source: Newsfilter
Clinical Trial Initiation: ModeX Therapeutics has initiated a Phase 1/2a clinical trial for MDX2004, a novel trispecific antibody-fusion protein aimed at treating advanced cancers and immune disorders by enhancing T cell activation.
Mechanism of Action: MDX2004 targets CD3, CD28, and 4-1BB to rejuvenate T cells, potentially improving immune responses in patients with advanced solid tumors and those with immune impairments due to various conditions.
Presentation at SITC: Two abstracts related to MDX2004 will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2025, showcasing preclinical and clinical data supporting its development.
About ModeX Therapeutics: ModeX is a biopharmaceutical company focused on developing multispecific biologics for cancer and infectious diseases, leveraging innovative platforms to create effective treatments for complex conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPK
Wall Street analysts forecast OPK stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.390
Low
2.25
Averages
2.75
High
3.00
Current: 1.390
Low
2.25
Averages
2.75
High
3.00
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Entera Bio Reports Preclinical Data for EB612 and EB618
- EB612 Clinical Data: Entera Bio's EB612 demonstrated robust bioavailability and sustained calcium increases across three preclinical models, with an IND application expected by late 2026, marking a significant advancement in treating hypoparathyroidism.
- Good Tolerability: In non-human primate models, a single oral dose of EB612 significantly raised serum calcium levels for three days without safety concerns, laying a solid foundation for its future clinical applications.
- EB618 Efficacy: As the first dual GLP-1/glucagon receptor agonist, EB618 exhibited dose-proportional pharmacokinetics in non-human primates and showed good tolerability even at doses exceeding the anticipated clinical range, supporting its potential in obesity and metabolic disorder treatments.
- Collaborative Development Strategy: Entera's partnership with OPKO Health has expanded, with both companies advancing EB612 on a 50/50 basis, showcasing Entera's strong R&D capabilities and market prospects in the oral peptide drug sector.
See More
OPKO Health Deepens Partnership with Nicoya Therapeutics
- Equity Investment Deepening: OPKO Health amended its agreement with Nicoya Therapeutics to acquire a 15% equity stake, further solidifying their partnership to commercialize RAYALDEE in Greater China, which is expected to enhance market penetration.
- Potential Revenue Assurance: While the equity change modifies the royalty and transfer pricing arrangements, OPKO remains eligible for up to $115 million in development, regulatory, and sales-based payments, ensuring future revenue stability.
- Market Demand Opportunity: With RAYALDEE already approved in Macau, both companies aim for additional regulatory approvals across China and related territories by 2027 to address the treatment needs of approximately 20 million adults suffering from stage 3 or 4 chronic kidney disease, showcasing significant market potential.
- Strategic Synergy: This collaboration leverages OPKO's integrated manufacturing and supply chain capabilities alongside Nicoya's localized clinical and commercial expertise, aligning with both companies' strategy to expand global patient access to RAYALDEE, indicating substantial growth opportunities in the underserved Asian renal health market.
See More
OPKO Health Q1 2026 Earnings Call Insights
- Product Development Progress: OPKO emphasized advancing its ModeX product development pipeline in Q1, with five programs now in the clinic, including the first subject dosed in the MDX2301 trial, showcasing the company's ongoing innovation in biopharmaceuticals.
- Partnership Value: The collaboration with Regeneron is expected to provide OPKO with over $1 billion in milestones and future royalties, serving as a significant source of nondilutive capital that enhances the company's financial stability.
- Financial Performance Overview: OPKO reported total revenues of $124.2 million for Q1 2026, with an operating loss of $51 million; however, the company is striving to achieve breakeven by mid-year, demonstrating resilience amid challenges.
- Future Outlook and Guidance: The company guided total revenue for Q2 2026 to be between $127 million and $132 million, while facing increased R&D spending pressures, it remains committed to expanding the 4Kscore market, emphasizing confidence in future growth.
See More
OPKO Health Q1 Financial Results Analysis
- Financial Performance: OPKO Health reported a Q1 GAAP EPS of -$0.07, aligning with expectations, yet revenue of $124.2 million fell 17.1% year-over-year, missing estimates by $6.57 million, indicating challenges in revenue growth.
- Cash Position: As of March 31, 2026, OPKO's cash, cash equivalents, and marketable securities totaled $341.9 million, with approximately $92 million of common stock repurchased since the program's authorization in July 2025, reflecting proactive capital management.
- Future Buyback Plans: In Q1 2026, OPKO repurchased $4.8 million in stock, with $108 million remaining authorized for future buybacks, demonstrating confidence in its stock value and commitment to shareholders.
- Financial Guidance: OPKO's revenue guidance for Q2 2026 is set at $72 million to $76 million for services and $38.4 million to $42.16 million for products, with unchanged full-year guidance, though market confidence in future growth remains to be strengthened.
See More
OPKO Health (OPK) Q4 2025 Earnings Call Transcript
See More
OPKO Health to Participate in 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: OPKO Health will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, where management will engage in one-on-one meetings with investors, showcasing the company's strategic positioning in the biopharmaceutical and diagnostics sectors.
- Live Webcast: On January 14 at 1:30 p.m. Pacific Time, management will participate in a fireside chat that will be webcast live, allowing investors to gain real-time insights into the company's latest developments and future directions.
- Investor Relations Enhancement: By facilitating direct communication with investors, OPKO Health aims to strengthen its market engagement, enhance its visibility in the biopharmaceutical industry, and further drive its market expansion efforts.
- Industry Positioning: OPKO Health is committed to establishing industry-leading positions in rapidly growing markets by leveraging its expertise in discovery, development, and commercialization, thereby demonstrating its innovative capabilities in the biopharmaceutical and diagnostics fields.
See More
Entera Bio Reports Preclinical Data for EB612 and EB618
- EB612 Clinical Data: Entera Bio's EB612 demonstrated robust bioavailability and sustained calcium increases across three preclinical models, with an IND application expected by late 2026, marking a significant advancement in treating hypoparathyroidism.
- Good Tolerability: In non-human primate models, a single oral dose of EB612 significantly raised serum calcium levels for three days without safety concerns, laying a solid foundation for its future clinical applications.
- EB618 Efficacy: As the first dual GLP-1/glucagon receptor agonist, EB618 exhibited dose-proportional pharmacokinetics in non-human primates and showed good tolerability even at doses exceeding the anticipated clinical range, supporting its potential in obesity and metabolic disorder treatments.
- Collaborative Development Strategy: Entera's partnership with OPKO Health has expanded, with both companies advancing EB612 on a 50/50 basis, showcasing Entera's strong R&D capabilities and market prospects in the oral peptide drug sector.
See More
OPKO Health Deepens Partnership with Nicoya Therapeutics
- Equity Investment Deepening: OPKO Health amended its agreement with Nicoya Therapeutics to acquire a 15% equity stake, further solidifying their partnership to commercialize RAYALDEE in Greater China, which is expected to enhance market penetration.
- Potential Revenue Assurance: While the equity change modifies the royalty and transfer pricing arrangements, OPKO remains eligible for up to $115 million in development, regulatory, and sales-based payments, ensuring future revenue stability.
- Market Demand Opportunity: With RAYALDEE already approved in Macau, both companies aim for additional regulatory approvals across China and related territories by 2027 to address the treatment needs of approximately 20 million adults suffering from stage 3 or 4 chronic kidney disease, showcasing significant market potential.
- Strategic Synergy: This collaboration leverages OPKO's integrated manufacturing and supply chain capabilities alongside Nicoya's localized clinical and commercial expertise, aligning with both companies' strategy to expand global patient access to RAYALDEE, indicating substantial growth opportunities in the underserved Asian renal health market.
See More
OPKO Health Q1 2026 Earnings Call Insights
- Product Development Progress: OPKO emphasized advancing its ModeX product development pipeline in Q1, with five programs now in the clinic, including the first subject dosed in the MDX2301 trial, showcasing the company's ongoing innovation in biopharmaceuticals.
- Partnership Value: The collaboration with Regeneron is expected to provide OPKO with over $1 billion in milestones and future royalties, serving as a significant source of nondilutive capital that enhances the company's financial stability.
- Financial Performance Overview: OPKO reported total revenues of $124.2 million for Q1 2026, with an operating loss of $51 million; however, the company is striving to achieve breakeven by mid-year, demonstrating resilience amid challenges.
- Future Outlook and Guidance: The company guided total revenue for Q2 2026 to be between $127 million and $132 million, while facing increased R&D spending pressures, it remains committed to expanding the 4Kscore market, emphasizing confidence in future growth.
See More
OPKO Health Q1 Financial Results Analysis
- Financial Performance: OPKO Health reported a Q1 GAAP EPS of -$0.07, aligning with expectations, yet revenue of $124.2 million fell 17.1% year-over-year, missing estimates by $6.57 million, indicating challenges in revenue growth.
- Cash Position: As of March 31, 2026, OPKO's cash, cash equivalents, and marketable securities totaled $341.9 million, with approximately $92 million of common stock repurchased since the program's authorization in July 2025, reflecting proactive capital management.
- Future Buyback Plans: In Q1 2026, OPKO repurchased $4.8 million in stock, with $108 million remaining authorized for future buybacks, demonstrating confidence in its stock value and commitment to shareholders.
- Financial Guidance: OPKO's revenue guidance for Q2 2026 is set at $72 million to $76 million for services and $38.4 million to $42.16 million for products, with unchanged full-year guidance, though market confidence in future growth remains to be strengthened.
See More
OPKO Health (OPK) Q4 2025 Earnings Call Transcript
See More
OPKO Health to Participate in 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: OPKO Health will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, where management will engage in one-on-one meetings with investors, showcasing the company's strategic positioning in the biopharmaceutical and diagnostics sectors.
- Live Webcast: On January 14 at 1:30 p.m. Pacific Time, management will participate in a fireside chat that will be webcast live, allowing investors to gain real-time insights into the company's latest developments and future directions.
- Investor Relations Enhancement: By facilitating direct communication with investors, OPKO Health aims to strengthen its market engagement, enhance its visibility in the biopharmaceutical industry, and further drive its market expansion efforts.
- Industry Positioning: OPKO Health is committed to establishing industry-leading positions in rapidly growing markets by leveraging its expertise in discovery, development, and commercialization, thereby demonstrating its innovative capabilities in the biopharmaceutical and diagnostics fields.
See More
